The purpose of this contract is to acquire genome characterization center (GCC) services consisting of large-scale, high- resolution, and comprehensive sequencing and array platforms. The sequencing…

Active Awarded Last action

Contract number
75N91025D00005
Awardee
Awarding agency
Task orders
2 $3,787,259 obligated

Award facts

Opportunity
Combined order value
  • $3,787,259 Current, with exercised options
  • $6,141,339 Potential, with all options
Last date to order 35% complete
IDV ceiling 3% used
$149,173,285.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 11 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Cancer Institute awarded a multiple-award IDIQ to Infinity Biologix LLC for genome characterization center services with a ceiling of $149.2 million and an ultimate completion date of January 12, 2030, effective January 13, 2025.

The contract procures large-scale, high-resolution genomic sequencing and array platforms, including whole exome sequencing. Infinity Biologix LLC operates as the Sampled Division and holds no SBA set-aside certifications. Work is performed at the prime's location in Piscataway, New Jersey.

The underlying solicitation was posted December 6, 2022, with proposal due date January 4, 2023. The contract is structured as a multiple-award IDIQ under the parent NCI Genomic Characterization Centers program. Seven task orders have been issued under this vehicle totaling $54.5 million.

The period of performance runs from January 13, 2025, through January 12, 2030. This contract reflects the National Cancer Institute's largest vehicle with Infinity Biologix, representing the bulk of the vendor's combined potential value across five federal agencies.

Description

The purpose of this contract is to acquire genome characterization center (GCC) services consisting of large-scale, high- resolution, and comprehensive sequencing and array platforms. The sequencing and array platforms include whole exome sequencing.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00004 · EO14398 the purpose of this bilateral modification is to comply with executive order 14398, addressing DEI discrimination by federal contractors. $0
Other Administrative Action P00003 · EOI:: implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025):: EOI $0
Supplemental Agreement for work within scope P00002 $0
Modification $0
Other Administrative Action P00001 $0

Quick answers

Who was awarded contract 75N91025D00005?

75N91025D00005 was awarded to Infinity Biologix LLC by National Cancer Institute (National Institutes of Health) on January 13, 2025.

How much is contract 75N91025D00005 worth?

Orders under 75N91025D00005 have obligated $3,787,259. Their combined potential value, with all options, is $6,141,339. 75N91025D00005's own ceiling is $149,173,285.

How many orders have been placed under contract 75N91025D00005?

2 orders have been placed under 75N91025D00005, the latest on September 25, 2026.

Who can order from contract 75N91025D00005?

75N91025D00005 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75N91025D00005 part of a contract vehicle?

Yes. 75N91025D00005 is part of NCI Genomic Characterization Centers.

Was contract 75N91025D00005 competed?

The extent of competition for 75N91025D00005 was full and open competition. The government received 11 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV